Grant: Discovery Grants Program - Individual
University of Toronto
$55,000.00
Harnessing Technological Advances to Re-engineer Polymer Particles for Drug Delivery
FY 2024-25
Summary
The COVID-19 pandemic has challenged the operations of scientific laboratories around the globe. Ironically, at the same time it is science and medicine that are leading us out of this pandemic. In fact, advanced pharmaceutical formulation is amongst the key areas that have played a critical role in the fight against COVID-19. The two clinically approved mRNA vaccines are reliant on formulation in lipid-based nanoparticles. This success has brought renewed interest in lipid and polymer particle-based formulation strategies. Pharmaceutical formulation involves combining drugs with inactive materials to produce products with desirable properties. Through formulation, pharmaceutical scientists can engineer important properties of new medicines, such as reduced side effects and improved therapeutic efficacy.
Polymers are materials that can be used for drug formulation. Polymers bring unparalleled diversity owing to the ability to synthesize innovative materials. Yet, to date the potential of polymer-based nano and microparticles for applications in drug formulation has not been fully exploited. This is in part due to the fact that there are a wide range of polymer properties and manufacturing parameters that must be considered in the development of nano or microparticle-based drug formulations. Further, the design - build - test loop associated with nano and microparticle development is largely reliant on hands on experimentation. Thus, full consideration of the impact of each polymer property or manufacturing parameter, and their combinations, on the characteristics and performance of drug formulations has been near to impossible to fully explore.
The goal of the proposed research program is to capitalize on recent technological advancements in artificial intelligence, machine learning, microfluidics and experimental automation to pursue data driven development pathways for polymeric nano and microparticle-based drug formulations. Over the past decade AI has enabled ground-breaking advances in the pharmaceutical and healthcare sectors, including improvements in drug discovery and cancer diagnosis. Machine learning is a branch of artificial intelligence, that enables computers to learn tasks without the need to be explicitly programmed. The proposed research aims to harness this technology to enable faster and cheaper design of more effective medicines for the treatment of chronic diseases with a high prevalence in women, including ovarian and breast cancer, osteoarthritis, and dementia. This research builds on areas of research strength and recent economic investment in Canada, namely, artificial intelligence and machine learning, manufacturing, and the biotech/pharmaceutical industry. As a result, this program will provide trainees with the knowledge and interdisciplinary skills necessary to secure leadership positions at the intersection between these growing industry sectors.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2022-04910
Name nom
Allen, Christine
Department département
Department of Pharmaceutical Sciences
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2022
Award amount
55000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Harnessing Technological Advances to Re-engineer Polymer Particles for Drug Delivery
Keywords
drug delivery; drug formulation; nanoparticle; microparticle; polymeric drug delivery; pharmaceutics; materials science; ai and machine learning; data-driven design
Application summary
The COVID-19 pandemic has challenged the operations of scientific laboratories around the globe. Ironically, at the same time it is science and medicine that are leading us out of this pandemic. In fact, advanced pharmaceutical formulation is amongst the key areas that have played a critical role in the fight against COVID-19. The two clinically approved mRNA vaccines are reliant on formulation in lipid-based nanoparticles. This success has brought renewed interest in lipid and polymer particle-based formulation strategies. Pharmaceutical formulation involves combining drugs with inactive materials to produce products with desirable properties. Through formulation, pharmaceutical scientists can engineer important properties of new medicines, such as reduced side effects and improved therapeutic efficacy.
Polymers are materials that can be used for drug formulation. Polymers bring unparalleled diversity owing to the ability to synthesize innovative materials. Yet, to date the potential of polymer-based nano and microparticles for applications in drug formulation has not been fully exploited. This is in part due to the fact that there are a wide range of polymer properties and manufacturing parameters that must be considered in the development of nano or microparticle-based drug formulations. Further, the design - build - test loop associated with nano and microparticle development is largely reliant on hands on experimentation. Thus, full consideration of the impact of each polymer property or manufacturing parameter, and their combinations, on the characteristics and performance of drug formulations has been near to impossible to fully explore.
The goal of the proposed research program is to capitalize on recent technological advancements in artificial intelligence, machine learning, microfluidics and experimental automation to pursue data driven development pathways for polymeric nano and microparticle-based drug formulations. Over the past decade AI has enabled ground-breaking advances in the pharmaceutical and healthcare sectors, including improvements in drug discovery and cancer diagnosis. Machine learning is a branch of artificial intelligence, that enables computers to learn tasks without the need to be explicitly programmed. The proposed research aims to harness this technology to enable faster and cheaper design of more effective medicines for the treatment of chronic diseases with a high prevalence in women, including ovarian and breast cancer, osteoarthritis, and dementia. This research builds on areas of research strength and recent economic investment in Canada, namely, artificial intelligence and machine learning, manufacturing, and the biotech/pharmaceutical industry. As a result, this program will provide trainees with the knowledge and interdisciplinary skills necessary to secure leadership positions at the intersection between these growing industry sectors.